| Bioactivity | Contezolid acefosamil (MRX-4) is the orally active prodrug of the active antimicrobial metabolite Contezolid (MRX-I), an oxazolidinone which shows potent in vitro activity against various multidrug-resistant Gram-positive bacteria, including MRSA[1]. |
| Name | Contezolid acefosamil |
| CAS | 1807497-11-5 |
| Formula | C20H18F3N4O8P |
| Molar Mass | 530.35 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Matteo Bassetti, et al. Innovative therapies for acute bacterial skin and skin-structure infections (ABSSSI) caused by methicillin-resistant Staphylococcus aureus: advances in phase I and II trials. Expert Opin Investig Drugs. 2020 May;29(5):495-506. |
Contezolid acefosamil
CAS: 1807497-11-5 F: C20H18F3N4O8P W: 530.35
Contezolid acefosamil (MRX-4) is the orally active prodrug of the active antimicrobial metabolite Contezolid (MRX-I), an
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.